SCHEMBL5281607

SCHEMBL5281607

COC(=O)C(N)S(=O)(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
ATM Q13315 1/20 0.46
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
SLC1A3 P43003 2/20 0.42
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
MEN1 O00255 1/20 0.42
LARS1 Q9P2J5 1/20 0.42
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097619 0.80 CA12 (0.51) KMT2AATMLMNAALDH1A1SMN1; SMN2
SCHEMBL5283948 0.79 ATM (0.38) KMT2AATMLMNACA12CA1
SCHEMBL11883834 0.79 SLC1A3 (0.49) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL3243611 0.78 ATM (0.37) ATMLMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL14477997 0.77 KMT2A (0.46) KMT2AATMLMNAALDH1A1SMN1; SMN2
SCHEMBL3246102 0.77 CYP3A4 (0.47) KMT2AATMLMNAALDH1A1SMN1; SMN2
SCHEMBL7427354 0.76 CTSD (0.48) KMT2AATMLMNAALDH1A1SMN1; SMN2
SCHEMBL5401263 0.76 TSHR (0.53) KMT2ASMN1; SMN2CA12CA1CA2
SCHEMBL5286324 0.76 KMT2A (0.50) KMT2AMAPTCA12CA1CA2
SCHEMBL26047552 0.76 ATM (0.50) KMT2AATMLMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KMT2A 4422/4885ATM 4711/4885LMNA 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.